Plas Matthijs, Kampschreur Linda M, Kroes Johannes A, Porcelijn Leendert, Bethlehem Carina
Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Eur J Hosp Pharm. 2025 Jun 24;32(4):385-387. doi: 10.1136/ejhpharm-2024-004165.
We present a case of drug-induced immune thrombocytopenia (DITP) proven to be due to ceftriaxone instead of assumed tuberculostatic treatment in a patient with miliary tuberculosis. It is important to identify the culprit drug in DITP to avoid discontinuing essential treatment, especially when more than one drug is implicated. In these cases additional analysis (drug-dependent platelet antibody testing) should be considered to prevent unnecessary replacement of a first-line regimen of tuberculostatic treatment with an alternative treatment regime.
我们报告了一例药物性免疫性血小板减少症（DITP）病例，该病例被证实是由头孢曲松引起的，而非一名粟粒性肺结核患者所假定的抗结核治疗药物。在DITP中识别出罪魁祸首药物很重要，以避免中断必要的治疗，尤其是当涉及多种药物时。在这些情况下，应考虑进行额外分析（药物依赖性血小板抗体检测），以防止用替代治疗方案不必要地替换一线抗结核治疗方案。
